A/HRC/23/51 - Office of the High Commissioner on Human Rights

More documents

Recommendations

Info

88 Date Type 31/07/2012 JUA 16/08/2012 AL Case No Country Mandate(s) Summary <strong>of</strong> <strong>the</strong> allegation transmitted Reply ETH 4/2012 Ethiopia TUN 3/2012 Tunisie Freedom <strong>of</strong> expression; Freedom <strong>of</strong> peaceful assembly and <strong>of</strong> association; Human rights defenders; Terrorism; Discrimination against women in law and in practice; Alleged sentencing <strong>of</strong> human rights defender. According to <strong>the</strong> information received, on 27 June 2012, Mr. Eskinder Nega Fenta along with journalists Messrs. Mesfin Negash, Abiye Teklemariam, Abebe Gellaw, Abebe Belew and Fasil Yenealem, who were reportedly in exile and tried in absentia, were found guilty <strong>of</strong> charges related to terrorism, treason and espionage under <strong>the</strong> Criminal Code <strong>of</strong> Ethiopia and <strong>the</strong> Anti-Terrorism Law. According to reports, <strong>the</strong> presiding judge accused <strong>the</strong> journalists <strong>of</strong> ―attempting to incite violence and overthrow <strong>the</strong> constitutional order‖ and <strong>the</strong> prosecutor allegedly requested sentences <strong>of</strong> life imprisonment. On 13 July 2012, Mr. Eskinder Nega Fenta was reportedly sentenced to 18 years in prison. The prominent journalist and blogger, along with <strong>23</strong> o<strong>the</strong>r individuals, were charged with terrorism-related <strong>of</strong>fenses in November 2011, reportedly in connection with an article Mr. Nega Fenta wrote in September 2011, in which he called for greater freedom <strong>of</strong> expression and <strong>of</strong> association in Ethiopia. Mr. Nega Fenta was <strong>the</strong> subject <strong>of</strong> previous communications (see A/<strong>HRC</strong>/20/30, case no ETH 7/2011). Préoccupations relatives à l'élaboration de la future Constitution de la République tunisienne, en particulier son article 28. Selon les informations reçues, cet article régresse sur les réalisations historiques de la Tunisie en matière d'égalité et des droits humains des femmes. Il prévoit que le rôle des femmes est également complémentaire à celui des hommes au sein de la famille." Le terme de «complémentarité» est une régression par rapport à l '«égalité» prévue dans la législation tunisienne précédente, y compris dans le Code du Statut Personnel de 1956. 14/12/2012 09/11/2012 19/12/2012 A/<strong>HRC</strong>/<strong>23</strong>/<strong>51</strong>
Date Type 21/08/2012 AL 21/08/2012 AL Case No Country Mandate(s) Summary <strong>of</strong> <strong>the</strong> allegation transmitted Reply OTH 9/2012 O<strong>the</strong>r OTH 10/2012 O<strong>the</strong>r Health; Health; Alleged negative impact <strong>of</strong> article 9 <strong>of</strong> <strong>the</strong> draft Deep and Comprehensive Free Trade Agreement (DCFTA), currently being negotiated between <strong>the</strong> Republic <strong>of</strong> Moldova and <strong>the</strong> European Union, on access to medicines in <strong>the</strong> Republic <strong>of</strong> Moldova. According to <strong>the</strong> information received, article 9 <strong>of</strong> <strong>the</strong> draft DCFTA contains a ―TRIPS-plus‖ provision on data exclusivity, according to which manufacturers <strong>of</strong> generic medicines would allegedly not be able to refer to clinical test results <strong>of</strong> originator drugs for a maximum period <strong>of</strong> eleven years with potentially negative impact on <strong>the</strong> ability <strong>of</strong> major segments <strong>of</strong> <strong>the</strong> population in Moldova to afford a range <strong>of</strong> medications, including antibiotics, antiretrovirals and medicines for <strong>the</strong> treatment <strong>of</strong> tuberculosis and cancer. Allegedly <strong>the</strong> provision will ensure a monopoly by manufacturers <strong>of</strong> originator drugs and that manufacturers <strong>of</strong> generic drugs will be unable to enter <strong>the</strong> market and provide cheaper alternatives to originator drugs for a maximum period <strong>of</strong> eleven years. Alleged negative impact <strong>of</strong> article 9 <strong>of</strong> <strong>the</strong> draft Deep and Comprehensive Free Trade Agreement (DCFTA), currently being negotiated between <strong>the</strong> Republic <strong>of</strong> Moldova and <strong>the</strong> European Union, on access to medicines in <strong>the</strong> Republic <strong>of</strong> Moldova. According to <strong>the</strong> information received, article 9 <strong>of</strong> <strong>the</strong> draft DCFTA contains a ―TRIPS-plus‖ provision on data exclusivity, according to which manufacturers <strong>of</strong> generic medicines would allegedly not be able to refer to clinical test results <strong>of</strong> originator drugs for a maximum period <strong>of</strong> eleven years with potentially negative impact on <strong>the</strong> ability <strong>of</strong> major segments <strong>of</strong> <strong>the</strong> population in Moldova to afford a range <strong>of</strong> medications, including antibiotics, antiretrovirals and medicines for <strong>the</strong> treatment <strong>of</strong> tuberculosis and cancer. Allegedly <strong>the</strong> provision will ensure a monopoly by manufacturers <strong>of</strong> originator drugs and that manufacturers <strong>of</strong> generic drugs will be unable to enter <strong>the</strong> market and provide cheaper alternatives to originator drugs for a maximum period <strong>of</strong> eleven years. 29/10/2012 29/10/2012 A/<strong>HRC</strong>/<strong>23</strong>/<strong>51</strong> 89
Page 1 and 2:
United Nations General Assembly Dis
Page 3 and 4:
A/HRC/23</
Page 5 and 6:
A/HRC/23</
Page 7 and 8:
A/HRC/23</
Page 9 and 10:
A/HRC/23</
Page 11 and 12:
Date Type 04/12/2012 AL 04/12/2012
Page 13 and 14:
Date Type 05/12/2012 JUA 05/12/2012
Page 15 and 16:
Date Type Case No Country Mandate(s
Page 17 and 18:
Date Type 10/12/2012 JUA 10/12/2012
Page 19 and 20:
Date Type 11/12/2012 AL 11/12/2012
Page 21 and 22:
Page 23 and 24:
Date Type 14/12/2012 AL Case No Cou
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Date Type 21/12/2012 JAL 21/12/2012
Page 31 and 32:
Date Type 21/12/2012 JUA 21/12/2012
Page 33 and 34:
Date Type 27/12/2012 JAL 28/12/2012
Page 35 and 36:
Date Type 28/12/2012 JUA 02/01/2013
Page 37 and 38: Date Type Case No Country Mandate(s
Page 41 and 42: Date Type 14/01/2013 JUA 15/01/2013
Page 45 and 46: Date Type 17/01/2013 JAL 17/01/2013
Page 61 and 62: Date Type 12/02/2013 AL 12/02/2013
Page 73 and 74: B. Replies received between 1 Febru
Page 77 and 78: 77 Date Type 19/12/2011 UA 09/02/20
Page 79 and 80: Date Type 02/04/2012 JAL Case No Co
Page 87: Date Type 16/07/2012 JAL 18/07/2012
Page 101 and 102: 101 Date Type 13/11/2012 AL 15/11/2
Page 103 and 104: 103 Date Type 23/1
Page 107 and 108: A/HRC/23</
show all

A/HRC/23/51 - Office of the High Commissioner on Human Rights

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?